Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabe...( Changes Will Result in a 35% Sales Fo...)

Changes Will Result in a 35% Sales Force Reduction and Approximately $45 Million Annual GAAP Operating Results Benefit

SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced a new approach to sales within the diabetes market. Amylin's existing primary care and specialty sales forces will merge into a single organization that brings a specialty approach to endocrinologists and diabetes-focused primary care physicians. The changes are expected to be implemented in the next several weeks and will reduce the total number of Amylin sales representatives by approximately 35 percent, or 200 employees, and will result in an annualized benefit of approximately $45 million to GAAP operating results in 2010.

The new sales approach is part of Amylin's continuing efforts to improve the efficiency and effectiveness of exenatide alliance operations with partner Eli Lilly and Company, and to maximize the value of the Company's current and future portfolio of first-in-class diabetes products. The changes to Amylin's field sales organization will be coordinated and aligned with the continuing exenatide sales efforts of Lilly. Amylin's resulting field sales organization will include approximately 325 sales representatives focused on endocrinologists and other physicians that treat significant numbers of diabetes patients. Lilly will continue their efforts within the endocrinology and larger primary care prescriber market to support BYETTA(R) (exenatide) injection. Overall, these changes will better position the companies for the anticipated launch of exenatide once weekly.

"This new, more focused approach to sales optimizes Amylin's sales organization for our portfolio today and in the future, and will enable us to improve the quality of our interactions with core prescribers through m
'/>"/>